Transport
Brighton Community Hospital Association
Brighton Community Hospital Association was paid $13.08M by Medicaid between Jan 2018 and Dec 2024, across 107 billing codes. Its largest line is 99283, emergency room visit (moderate) — 34% of everything it billed.
33Billing provider infoBRIGHTON COMMUNITY HOSPITAL ASSOCIATION
BRIGHTON, CO 80601
BRIGHTON, CO 80601
33aNPI1629071758assigned 05/23/2005
33bProvider typeLand Ambulance
28Total paid$13.08M
24GClaims404,650
24DCodes billed107
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Land Ambulance providers in Colorado
Rank by total paid#3 of 98
Median peer was paid$202K
This provider vs. median65×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,982 | $1.28M | |
| 2019 | 40,322 | $1.26M | |
| 2020 | 37,735 | $1.09M | |
| 2021 | 57,162 | $1.56M | |
| 2022 | 85,144 | $2.73M | |
| 2023 | 87,876 | $2.94M | |
| 2024incomplete | 57,429 | $2.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 34% | 32,149 | 29,172 | $4.45M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 30,952 | 27,601 | $3.88M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.1% | 8,719 | 7,392 | $1.19M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.7% | 3,007 | 2,571 | $871K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.1% | 3,702 | 3,194 | $660K |
| 80053 | Comprehensive metabolic panel | 3.4% | 30,909 | 26,768 | $448K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.2% | 3,718 | 3,276 | $284K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 7,149 | 2,146 | $198K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 759 | 631 | $132K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,124 | 446 | $122K |
| J3490 | Unclassified drugs | <1% | 68,561 | 34,941 | $112K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,301 | 397 | $80K |
95 more codes
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 773 | $73K |
| 84484 | <1% | 8,052 | $70K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,434 | $56K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 367 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 871 | $52K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 724 | $47K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 99 | $36K |
| 80320 | <1% | 304 | $31K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 44,108 | $23K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 175 | $23K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 22,169 | $22K |
| 83605 | <1% | 1,575 | $15K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,711 | $15K |
| 97161 | <1% | 215 | $12K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 55 | $10K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,791 | $9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 711 | $9K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 728 | $7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,100 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,215 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 192 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 924 | $6K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 191 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,406 | $5K |
| 87040 | <1% | 391 | $5K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 389 | $4K |
| 80061 | Lipid panel | <1% | 466 | $4K |
| 81001 | <1% | 20,735 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,190 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 309 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 15 | $3K |
| G0378 | Hospital observation service, per hour | <1% | 25 | $3K |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 153 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,126 | $2K |
| 86780 | <1% | 193 | $1K | |
| 84145 | <1% | 154 | $1K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 22 | $1K |
| 80076 | <1% | 338 | $942.60 | |
| 84703 | <1% | 6,114 | $903.28 | |
| 97597 | <1% | 17 | $877.31 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13 | $826.51 |
| 85379 | <1% | 79 | $795.55 | |
| 85027 | <1% | 122 | $726.27 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 112 | $638.16 |
| 86592 | <1% | 14 | $590.50 | |
| 83880 | <1% | 16 | $574.96 | |
| 83690 | <1% | 5,509 | $467.26 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 520 | $430.94 |
| 80055 | <1% | 13 | $394.82 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 88 | $318.38 |
| 82728 | <1% | 40 | $312.52 | |
| 83550 | <1% | 39 | $189.37 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,087 | $163.90 |
| 86850 | <1% | 40 | $146.80 | |
| 83540 | <1% | 39 | $146.59 | |
| 81025 | <1% | 297 | $133.16 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 10,202 | $122.57 |
| 36591 | <1% | 26 | $111.44 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 15 | $110.77 |
| 83735 | <1% | 928 | $93.28 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 17 | $76.22 |
| 86900 | <1% | 40 | $72.41 | |
| 87340 | <1% | 25 | $64.94 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,014 | $50.82 |
| 82950 | <1% | 12 | $48.61 | |
| 86901 | <1% | 40 | $36.70 | |
| 86787 | <1% | 13 | $32.22 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,037 | $31.32 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,163 | $21.18 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 937 | $5.95 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 680 | $2.24 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 342 | $1.34 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 1,041 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 172 | $0.00 |
| 86140 | 0% | 67 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 947 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 42 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 206 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 223 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 100 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 187 | $0.00 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 108 | $0.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 16 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 53 | $0.00 |
| 88304 | 0% | 80 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 27 | $0.00 |
| 87088 | 0% | 25 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 363 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 148 | $0.00 |
| 85610 | 0% | 279 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 390 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 33 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 14 | $0.00 |
| 80306 | 0% | 19 | $0.00 | |
| 84100 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMANSON, BRYAN (VP FIANCE)
Parent organizationINTEGRITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Uptown Community Health Center INC | Denver, CO | $466K |
| Uptown Community Health Center INC | Denver, CO | $43K |
| Uptown Community Health Center INC | Denver, CO | $10K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.